A Phase 1 Study of UCN-01 in Combination With Perifosine in Patients With Relapsed and Refractory Acute Leukemias and High Risk MDS [Myelodysplastic syndromes].

Trial Profile

A Phase 1 Study of UCN-01 in Combination With Perifosine in Patients With Relapsed and Refractory Acute Leukemias and High Risk MDS [Myelodysplastic syndromes].

Completed
Phase of Trial: Phase I

Latest Information Update: 27 Sep 2013

At a glance

  • Drugs Perifosine (Primary) ; UCN 01 (Primary)
  • Indications Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Acute promyelocytic leukaemia; Chronic myeloid leukaemia; Myelodysplastic syndromes; Myeloproliferative disorders
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 Jul 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 06 Nov 2012 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top